Source comparison
BPC-157 for Vaccine Injury Recovery Research: Comparison of Evidence Quality
Rodent cardiovascular injury models Controlled interventional 34–47% reduction in inflammatory markers; preserved endothelial tight junctions; reduced myocardial scar tissue Species translation unknown; dosing not human-equivalent; healthy baseline models Mech
This comparison does not assign a generated winner or score.
- Rodent cardiovascular injury models
- Controlled interventional
- 34–47% reduction in inflammatory markers; preserved endothelial tight junctions; reduced myocardial scar tissue
- Species translation unknown; dosing not human-equivalent; healthy baseline models
- Mechanistic hypothesis generation only. Not sufficient for clinical recommendation
- In vitro endothelial assays
- Cell culture with inflammatory challenge
- BPC-157 preserved claudin-5 and occludin expression; reduced NF-κB activation by 52%
- Simplified system; lacks immune cell interaction; single-cell-type models
- Supports plausibility of endothelial protective mechanism but cannot predict in vivo human response
- Anecdotal case series (integrative clinics)
- Observational, no control group
- Patient-reported symptom improvement in 60–70% of cases; no objective biomarker tracking
- No standardised dosing; confounded by concurrent therapies; publication bias
- Cannot establish causality. Symptom improvement may reflect natural recovery timeline
- Human pharmacokinetic studies
- None published as of 2026
- N/A
- Complete absence of data on absorption, distribution, metabolism, excretion in humans
- Zero validated dosing guidance exists for any indication
- Regulatory clinical trials
- None registered or completed
- No Phase I, II, or III data for any indication including vaccine injury recovery
- Not approved for any therapeutic use. All applications are experimental